Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes

Dimethyl fumarate (DMF) is a first-line-treatment for relapsing-remitting multiple sclerosis (RRMS). The redox master regulator Nrf2, essential for redox balance, is a target of DMF, but its precise therapeutic mechanisms of action remain elusive. Here we show impact of DMF on circulating monocytes...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlström, Karl E., Ewing, Ewoud, Granqvist, Mathias, Gyllenberg, Alexandra, Aeinehband, Shahin, Enoksson, Sara Lind, Checa, Antonio, Badam, Tejaswi V. S., Huang, Jesse, Gomez-Cabrero, David, Gustafsson, Mika, Al Nimer, Faiez, Wheelock, Craig E., Kockum, Ingrid, Olsson, Tomas, Jagodic, Maja, Piehl, Fredrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626021/
https://www.ncbi.nlm.nih.gov/pubmed/31300673
http://dx.doi.org/10.1038/s41467-019-11139-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626021/
https://www.ncbi.nlm.nih.gov/pubmed/31300673
http://dx.doi.org/10.1038/s41467-019-11139-3

Ejemplares similares